Non-viral gene therapy offers hope for chronic low back pain sufferers

Pfiz­er and Val­ne­va said pa­tients demon­strat­ed “strong im­mune re­spons­es” af­ter re­ceiv­ing a sec­ond boost­er dose of their ex­per­i­men­tal Ly­me dis­ease vac­cine, sup­port­ing the case for

Emer­gent BioSo­lu­tions said its an­thrax vac­cine re­ceived full FDA ap­proval, though the com­pa­ny has pro­vid­ed dos­es of the vac­cine to the US gov­ern­ment for al­most